We are live on ! Find out more
OBIO icon

Orchestra BioMed
OBIO

62 hedge funds and large institutions have $140M invested in Orchestra BioMed in 2022 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 16 increasing their positions, 5 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

220% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 5

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

80% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 5

5% more funds holding

Funds holding: 59 → 62 (+3)

1.05% more ownership

Funds ownership: 68.8% → 69.84% (+1%)

2% more capital invested

Capital invested by funds: $138M → $140M (+$2.31M)

Holders
62
Holders Change
+3
Holders Change %
+5.08%
% of All Funds
1.04%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
9
Increased
16
Reduced
5
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$2.74M
2
Millennium Management
Millennium Management
New York
+$1.94M
3
WRBC
W.R. Berkley Corp
Connecticut
+$1.82M
4
KPF
K2 Principal Fund
Ontario, Canada
+$1.74M
5
LSC
Logan Stone Capital
Illinois
+$1.64M

Top Sellers

Rank Fund Capital Flow
1
DKCM
Davidson Kempner Capital Management
New York
-$4.97M
2
PA
Perceptive Advisors
New York
-$4.46M
3
AAA
Affinity Asset Advisors
New York
-$2.97M
4
SCM
Shaolin Capital Management
Florida
-$1.98M
5
M
Murchinson
Ontario, Canada
-$992K
Name Holding Trade Value Shares
Change 		Change in
Stake
D.E. Shaw & Co
1
D.E. Shaw & Co
New York
$9.35M +$512K +51,487 +6%
Adage Capital Partners
2
Adage Capital Partners
Massachusetts
$7.97M – – –
BlackRock
3
BlackRock
New York
$7.92M – – –
SCM
4
Saba Capital Management
New York
$7.34M – – –
T. Rowe Price Associates
5
T. Rowe Price Associates
Maryland
$7.24M -$665K -66,876 -8%
RCM
6
RA Capital Management
Massachusetts
$6.22M – – –
AC
7
Amitell Capital
Singapore
$5.98M – – –
SC
8
Sculptor Capital
New York
$5.41M +$513K +51,649 +11%
WRBC
9
W.R. Berkley Corp
Connecticut
$4.9M +$1.82M +183,363 +59%
CC
10
Centiva Capital
New York
$4.82M +$1.49M +149,505 +45%
DKCM
11
Davidson Kempner Capital Management
New York
$4.73M -$4.97M -500,000 -51%
RCM
12
Radcliffe Capital Management
Pennsylvania
$4.06M +$2.87K +289 +0.1%
WP
13
Woodline Partners
California
$4.02M – – –
APM
14
Avidity Partners Management
Texas
$3.98M – – –
BC
15
Boxer Capital
California
$3.98M – – –
EC
16
EcoR1 Capital
California
$3.98M – – –
ACP
17
Acuta Capital Partners
California
$3.91M – – –
WAM
18
Weiss Asset Management
Massachusetts
$3.05M +$99.4K +10,000 +3%
BFM
19
Boothbay Fund Management
New York
$2.98M +$925K +93,050 +45%
LSC
20
Logan Stone Capital
Illinois
$2.92M +$1.64M +165,237 +129%
Hudson Bay Capital Management
21
Hudson Bay Capital Management
Connecticut
$2.74M +$2.74M +275,298 New
Millennium Management
22
Millennium Management
New York
$2.53M +$1.94M +194,867 +327%
Citadel Advisors
23
Citadel Advisors
Florida
$2.5M -$106K -10,626 -4%
GL
24
Governors Lane
New York
$2.49M – – –
SCM
25
Sio Capital Management
New York
$2.49M – – –
1
2 3

OBIO Hedge Fund Activity: Q2 2022 in Review

62 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q2 2022, worth a combined $140M — up 1.7% from $138M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new OBIO positions and 5 closed out — a net gain of 4 holders — while 16 added to existing stakes and 5 trimmed.

The largest buyer was Hudson Bay Capital Management, opening a new position worth an estimated $2.74M. The largest seller was Davidson Kempner Capital Management, cutting an estimated $4.97M.

  • 62 institutional investors held Orchestra BioMed (OBIO) as of Q2 2022, up from 59 in Q1 2022.
  • Funds reported $140M of Orchestra BioMed stock for Q2 2022, up 1.7% quarter-over-quarter.
  • 9 funds opened new Orchestra BioMed positions in Q2 2022 and 5 closed out, a net change of +4 holders.
  • The largest Orchestra BioMed buyer in Q2 2022 was Hudson Bay Capital Management, an estimated $2.74M added.
  • The largest Orchestra BioMed seller in Q2 2022 was Davidson Kempner Capital Management, an estimated $4.97M sold.

Based on aggregated 13F filings for Q2 2022.